Abstract
BACKGROUND: Maternal serum screening is used to assist in the prenatal detection of congenital anomalies. Its use is controversial, and one concern that has been expressed is its psychological effects on women. The authors examined whether this test leads to an increase in anxiety and depression among women who have a false-positive result as compared with those who have a true-negative result or do not undergo testing. METHODS: A prospective cohort study with baseline assessment at 15 to 18 weeks' gestation and follow-up at 24 weeks' gestation was conducted. Pregnant women at 8 geographically diverse sites across Ontario were recruited. The main outcome measures were the state portion of the State--Trait Anxiety Inventory and the Center for Epidemiologic Studies Depression Scale. RESULTS: Of the 2418 potential subjects 2020 (83.5%) were enrolled and eligible; 1741 (86.2%) completed the follow-up. A total of 1177 women (67.6%) underwent maternal serum screening. No overall adverse psychological effects as a result of testing were found at 24 weeks' gestation. Women with a false-positive result had a mean increase in anxiety score of 1.6 (95% confidence interval [CI] -1.7 to 4.9), whereas women with a true-negative result had a mean decrease of 1.1 (95% CI -1.8 to -0.3) and those not tested had a mean decrease of 0.4 (95% CI -1.3 to 0.5). The mean depression score increased by 0.5 (95% CI -0.9 to 2.0) in the false-positive group, was unchanged (95% CI -0.3 to 0.4) in the true-negative group and increased by 0.2 (95% CI -1.7 to 1.2) in the not tested group. Of the women who underwent testing, 87 (7.6%) were unsure of their result at the time of follow-up. INTERPRETATION: The results suggest that maternal screening in Ontario is not causing serious psychological harm to women. Communication regarding test results could be improved, since a substantial proportion of women were unsure of their test result.
Full Text
The Full Text of this article is available as a PDF (229.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Carroll J. C., Reid A. J., Woodward C. A., Permaul-Woods J. A., Domb S., Ryan G., Arbitman S., Fallis B., Kilthei J. Ontario Maternal Serum Screening Program: practices, knowledge and opinions of health care providers. CMAJ. 1997 Mar 15;156(6):775–784. [PMC free article] [PubMed] [Google Scholar]
- Cheng E. Y., Luthy D. A., Zebelman A. M., Williams M. A., Lieppman R. E., Hickok D. E. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. Obstet Gynecol. 1993 Jan;81(1):72–77. [PubMed] [Google Scholar]
- Fearn J., Hibbard B. M., Laurence K. M., Roberts A., Robinson J. O. Screening for neural-tube defects and maternal anxiety. Br J Obstet Gynaecol. 1982 Mar;89(3):218–221. doi: 10.1111/j.1471-0528.1982.tb03618.x. [DOI] [PubMed] [Google Scholar]
- Goel V., Glazier R., Holzapfel S., Pugh P., Summers A. Evaluating patient's knowledge of maternal serum screening. Prenat Diagn. 1996 May;16(5):425–430. doi: 10.1002/(SICI)1097-0223(199605)16:5<425::AID-PD874>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
- Green J. M. Serum screening for Down's syndrome: experiences of obstetricians in England and Wales. BMJ. 1994 Sep 24;309(6957):769–772. doi: 10.1136/bmj.309.6957.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Haddow J. E., Palomaki G. E., Knight G. J., Williams J., Pulkkinen A., Canick J. A., Saller D. N., Jr, Bowers G. B. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992 Aug 27;327(9):588–593. doi: 10.1056/NEJM199208273270902. [DOI] [PubMed] [Google Scholar]
- Haynes R. B., Sackett D. L., Taylor D. W., Gibson E. S., Johnson A. L. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med. 1978 Oct 5;299(14):741–744. doi: 10.1056/NEJM197810052991403. [DOI] [PubMed] [Google Scholar]
- MacDonald M. L., Wagner R. M., Slotnick R. N. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age. Obstet Gynecol. 1991 Jan;77(1):63–68. [PubMed] [Google Scholar]
- Marteau T. M. Towards informed decisions about prenatal testing: a review. Prenat Diagn. 1995 Dec;15(13):1215–1226. doi: 10.1002/pd.1970151304. [DOI] [PubMed] [Google Scholar]
- Nørgaard-Pedersen B., Larsen S. O., Arends J., Svenstrup B., Tabor A. Maternal serum markers in screening for Down syndrome. Clin Genet. 1990 Jan;37(1):35–43. doi: 10.1111/j.1399-0004.1990.tb03388.x. [DOI] [PubMed] [Google Scholar]
- Phillips O. P., Elias S., Shulman L. P., Andersen R. N., Morgan C. D., Simpson J. L. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol. 1992 Sep;80(3 Pt 1):353–358. [PubMed] [Google Scholar]
- Phipps S., Zinn A. B. Psychological response to amniocentesis: II. Effects of coping style. Am J Med Genet. 1986 Sep;25(1):143–148. doi: 10.1002/ajmg.1320250116. [DOI] [PubMed] [Google Scholar]
- Wald N. J., Cuckle H. S., Densem J. W., Nanchahal K., Royston P., Chard T., Haddow J. E., Knight G. J., Palomaki G. E., Canick J. A. Maternal serum screening for Down's syndrome in early pregnancy. BMJ. 1988 Oct 8;297(6653):883–887. doi: 10.1136/bmj.297.6653.883. [DOI] [PMC free article] [PubMed] [Google Scholar]